NasdaqGS:GERNBiotechs
Can Geron’s (GERN) Narrowing Losses Reframe Expectations For Its Blood Cancer Earnings Potential?
Geron Corporation has already reported first-quarter 2026 results, with revenue rising to US$51.84 million from US$39.6 million and net loss narrowing to US$3.64 million from US$19.84 million a year earlier, while also outlining upcoming May investor conference presentations on its blood cancer programs.
The sharp reduction in quarterly net loss and loss per share, achieved alongside higher revenue, highlights how Geron’s commercial ramp is affecting its income statement.
We’ll now examine...